| + |
BIRC2 | down-regulates quantity by destabilization 
ubiquitination, polyubiquitination
|
PACS2 |
0.306 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-278742 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 24633224 |
The principal findings indicate that (i) PACS-2 is constitutively polyubiquitinated and degraded via the proteasome pathway in liver cells; (ii) Cellular Inhibitor of Apoptoses bind to and directly ubiquitinate PACS-2; (iii) pharmacological depletion (by SMAC mimetics) or genetic deletion of both cIAP-1 and cIAP-2 impairs PACS-2 ubiquitination and results in its intracellular accumulation; and (iv) PACS-2 accumulation facilitates its translocation to the lysosomes following TRAIL treatment, promoting TRAIL-induced lysosomal membrane permeabilization and apoptosis.|Therefore, it appears that cIAP-1 and cIAP-2 act coordinately and redundantly to ubiquitinate PACS-2. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-278743 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 24633224 |
The principal findings indicate that (i) PACS-2 is constitutively polyubiquitinated and degraded via the proteasome pathway in liver cells; (ii) Cellular Inhibitor of Apoptoses bind to and directly ubiquitinate PACS-2; (iii) pharmacological depletion (by SMAC mimetics) or genetic deletion of both cIAP-1 and cIAP-2 impairs PACS-2 ubiquitination and results in its intracellular accumulation; and (iv) PACS-2 accumulation facilitates its translocation to the lysosomes following TRAIL treatment, promoting TRAIL-induced lysosomal membrane permeabilization and apoptosis.|The principal findings indicate that (i) PACS-2 is constitutively polyubiquitinated and degraded via the proteasome pathway in liver cells; (ii) cIAPs bind to and directly ubiquitinate PACS-2; (iii) pharmacological depletion (by SMAC mimetics) or genetic deletion of both cIAP-1 and cIAP-2 impairs PACS-2 ubiquitination and results in its intracellular accumulation; and (iv) PACS-2 accumulation facilitates its translocation to the lysosomes following TRAIL treatment, promoting TRAIL induced LMP and apoptosis. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-272851 |
|
|
in vitro |
|
| pmid |
sentence |
| 24633224 |
Under basal conditions, PACS-2 underwent K48-linked poly-ubiquitination, resulting in PACS-2 proteasomal degradation. Biochemical assays showed cIAP-1 and cIAP-2 interacted with PACS-2 in vitro and co-immunoprecipitation studies demonstrated that the two cIAPs bound PACS-2 in vivo. More importantly, both cIAP-1 and cIAP-2 directly mediated PACS-2 ubiquitination in a cell-free assay. |
|
| Publications: |
3 |
Organism: |
Homo Sapiens, In Vitro |
| + |
BIRC3 | down-regulates quantity by destabilization
polyubiquitination
|
PACS2 |
0.288 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-272852 |
|
|
in vitro |
|
| pmid |
sentence |
| 24633224 |
Under basal conditions, PACS-2 underwent K48-linked poly-ubiquitination, resulting in PACS-2 proteasomal degradation. Biochemical assays showed cIAP-1 and cIAP-2 interacted with PACS-2 in vitro and co-immunoprecipitation studies demonstrated that the two cIAPs bound PACS-2 in vivo. More importantly, both cIAP-1 and cIAP-2 directly mediated PACS-2 ubiquitination in a cell-free assay. |
|
| Publications: |
1 |
Organism: |
In Vitro |
3.0
PACS2
- 
- 